Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials
Authors:
- Susan ZiescheSZSusan Ziesche
- Gary JohnsonGJGary Johnson
- Jay N. CohnJCJay N. Cohn
- 1 September 1999
- journal article
- clinical trial
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 5 (3) , 178-187
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.Journal of Clinical Investigation, 1996
- Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failureJACC, 1995
- Hospitalization for congestive heart failure. Explaining racial differencesJAMA, 1995
- Racial Differences in Epinephrine and β2-Adrenergic ReceptorsHypertension, 1995
- Racial Differences in the Use of Invasive Cardiovascular Procedures in the Department of Veterans Affairs Medical SystemNew England Journal of Medicine, 1993
- The interaction of norepinephrine excretion with blood pressure and race in childrenJournal Of Hypertension, 1992
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986
- Sodium and water balance in chronic congestive heart failure.Journal of Clinical Investigation, 1986
- Renin system activity as a determinant of response to treatment in hypertension and heart failure.Hypertension, 1983
- Pathophysiology of hypertension in blacks and whites. A review of the basis of racial blood pressure differences.Hypertension, 1979